Tag Line
Choose
   
   

 
Home • Product Candidates • Our Pipeline
Our Pipeline

We have established a diverse portfolio of proprietary product development programs, that includes both pharmaceuticals and biologics.  Our pharmaceutical development programs are focused on developing novel treatments for obesity, as well as for attention and cognitive disorders and other indications.  In addition, we are developing a patented and proprietary stem cell product, MultiStem, that we believe has potential for treating multiple disease conditions, including in the cardiovascular, oncology, and neurological areas. 

Since the summer of 2007, we have advanced several programs into clinical development, across a range of disease areas, including obesity, cancer treatment support, and cardiovascular disease.  We believe that our pipeline can be broadened over time, driven by our technologies, capabilities and approach.  In particular, we believe that MultiStem has significant therapeutic potential across a range of clinical indications, such as for treating ischemic injury and immune system disorders. 

By maintaining a lean infrastructure, and working collaboratively with others, including leading academic researchers, clinical centers, contract research organizations, and contract manufacturing organizations, we are able to efficiently and cost effectively advance multiple programs in parallel. 

 
Development Status of Key Programs

 
 

MultiStem programs. The company has advanced multiple MultiStem programs to clinical development. In 2008 we initiated phase I clinical trials evaluating the administration of MultiStem following acute myocardial infarction and as an adjunctive treatment for bone marrow/hematopoetic stem cell transplantation. In December of 2008 we received authorization from the FDA to initiate a third Phase I clinical trial involving administration of MultiStem to patients that have suffered an ischemic stroke. We are interested in the potential application of MultiStem toward treating a range of diseases, including those involving ischemic injury, autoimmune disease and other conditions involving immune system function, and other indications.  Working with independent collaborators we are conducting preclinical research in multiple areas.

Additional information will be provided as submitted IND's are approved, as new trials are initiated, or as trials achieve important milestones.  Further information about these and other trials may be available at www.clinicaltrials.gov.
Summary

5HT2c Agonists for obesity.  In addition to our MultiStem programs, we are developing pharmaceuticals for the treatment of obesity and certain neurological conditions associated with cognition, attention and wakefulness. In the obesity area, we are developing compounds that selectively stimulate the 5HT2c serotonin receptor in the brain, which is known to play an important role in regulating appetite. These compounds, known as 5HT2c agonists, are designed to reduce appetite and food intake, in order to achieve substantial weight loss over time.  

Histamine H3 Receptor Antagonists.  The H3 receptor regulates levels of histamine and other neuro-transmitters in certain areas of the brain that play a direct role in regulating sleep and cognitive function. Our histamine H3 receptor antagonists represent a new class of drugs that could have an improved efficacy and safety profile relative to existing drugs used for the treatment of conditions that affect cognition, attention and wakefulness.